Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$86.02
-1.7%
$83.47
$73.31
$111.58
$218.56B0.3714.01 million shs11.22 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$26.83
-2.5%
$25.92
$23.15
$59.73
$10.75B2.0112.07 million shs10.05 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-1.55%-3.62%+2.34%+3.21%-22.00%
Moderna, Inc. stock logo
MRNA
Moderna
-2.54%-5.83%+10.37%-20.24%-54.42%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$86.02
-1.7%
$83.47
$73.31
$111.58
$218.56B0.3714.01 million shs11.22 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$26.83
-2.5%
$25.92
$23.15
$59.73
$10.75B2.0112.07 million shs10.05 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-1.55%-3.62%+2.34%+3.21%-22.00%
Moderna, Inc. stock logo
MRNA
Moderna
-2.54%-5.83%+10.37%-20.24%-54.42%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.29
Hold$104.3121.26% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.00
Hold$41.8155.84% Upside

Current Analyst Ratings Breakdown

Latest MRNA and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/10/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$31.00 ➝ $32.00
10/8/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/8/2025
Moderna, Inc. stock logo
MRNA
Moderna
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
9/27/2025
Moderna, Inc. stock logo
MRNA
Moderna
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/17/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold$100.00 ➝ $90.00
8/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetUnderperform$18.00 ➝ $15.00
8/4/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$40.00 ➝ $31.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$32.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$26.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$40.00
(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$64.17B3.35$9.31 per share9.24$18.33 per share4.69
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.24N/AN/A$28.33 per share0.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.4913.258.690.9025.79%41.05%16.55%10/30/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%11/6/2025 (Estimated)

Latest MRNA and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$1.95N/AN/AN/A$893.29 millionN/A
10/30/2025Q3 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.37N/AN/AN/A$17.00 billionN/A
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
7/29/2025Q2 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.03$2.13+$0.10$1.76$15.92 billion$15.81 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.243.77%N/A49.92%14 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest MRNA and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/22/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.814%9/15/20259/15/202510/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.69
1.42
1.17
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77

Institutional Ownership

CompanyInstitutional Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.13%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.50 billion2.49 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800390.58 million347.62 millionOptionable

Recent News About These Companies

4 Analysts Assess Moderna: What You Need To Know
Moderna (NASDAQ:MRNA) Given Sell (E+) Rating at Weiss Ratings
Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of "Hold" by Analysts
Funds dry up for mRNA vaccines amid US political storm
Dave Gammon: mRNA technology is the future of vaccines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$86.02 -1.48 (-1.69%)
Closing price 10/10/2025 03:59 PM Eastern
Extended Trading
$85.45 -0.57 (-0.67%)
As of 10/10/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Moderna stock logo

Moderna NASDAQ:MRNA

$26.83 -0.70 (-2.54%)
Closing price 10/10/2025 04:00 PM Eastern
Extended Trading
$26.52 -0.31 (-1.15%)
As of 10/10/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.